Paragon Equity acquires 10% of BresaGen

By Ruth Beran
Tuesday, 16 August, 2005

Adelaide-based venture and development capital firm Paragon Equity has invested more than $AUD850,000 to acquire a 10 per equity holding of Adelaide biopharma BresaGen (ASX:BGN).

The investment consists of an issue of 13.9 million shares in new equity. Ten million shares result from the purchase and conversion of five convertible notes which were approved by shareholders on May 24 and converted at $0.05 per share.

The further 3.9 million shares were acquired at $0.09, a 10 per cent discount to the five day volume weighted average price of BresaGen's stock.

Subject to shareholder approval, Paragon Equity has also been granted over 3.9 million unlisted options at an exercise price of $0.12 with a five year expiry date.

"The investment into BresaGen is a long-term investment for Paragon," said Paragon Advisory executive chairman Greg Boulton in a statement.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd